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ARTICLE
Physical Exercise–Induced Hypoglycemia Caused by Failed
Silencing of Monocarboxylate Transporter 1 in Pancreatic b Cells
Timo Otonkoski, Hong Jiao, Nina Kaminen-Ahola, Isabel Tapia-Paez, Mohammed S. Ullah,
Laura E. Parton, Frans Schuit, Roel Quintens, Ilkka Sipila¨, Ertan Mayatepek, Thomas Meissner,
Andrew P. Halestrap, Guy A. Rutter, and Juha Kere
Exercise-induced hyperinsulinism (EIHI) is a dominantly inherited hypoglycemic disorder characterized by inappropriate
insulin secretion during anaerobic exercise or on pyruvate load. We aimed to identify the molecular basis of this novel
disorder of b-cell regulation. EIHI mapped to chromosome 1 (LOD score 3.6) in a genome scan performed for two families
with 10 EIHI-affected patients. Mutational analysis of the promoter of the SLC16A1 gene,which encodesmonocarboxylate
transporter 1 (MCT1), located under the linkage peak, revealed changes in all 13 identiﬁed patients with EIHI. Patient
ﬁbroblasts displayed abnormally high SLC16A1 transcript levels, although monocarboxylate transport activities were not
changed in these cells, reﬂecting additional posttranscriptional control of MCT1 levels in extrapancreatic tissues. By
contrast, when examined in b cells, either of two SLC16A1 mutations identiﬁed in separate pedigrees resulted in increased
protein binding to the corresponding promoter elements and marked (3- or 10-fold) transcriptional stimulation of
SLC16A1 promoter-reporter constructs. These studies show that promoter-activating mutations in EIHI induce SLC16A1
expression in b cells, where this gene is not usually transcribed, permitting pyruvate uptake and pyruvate-stimulated
insulin release despite ensuing hypoglycemia. These ﬁndings describe a novel disease mechanism based on the failure
of cell-speciﬁc transcriptional silencing of a gene that is highly expressed in other tissues.
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Release of insulin from the pancreatic b cell is carefully
controlled by metabolic demands, allowing maintenance
of the circulating blood-glucose concentrationwithinnar-
row physiological limits. It is therefore important that in-
sulin release be strongly stimulated as glucose concentra-
tions rise but also effectively switched off during fasting,
to avoid hypoglycemia.1 b-cellmetabolismhas speciﬁc fea-
tures to ensure the latter. First, b cells express the low-
afﬁnity glucose transporter GLUT22 and glucose phos-
phorylating activity, glucokinase,3 to permit enhanced
glucose metabolism as the concentration of the sugar
changes over the physiological range.1 Second, the activity
of lactate dehydrogenase is unusually low.4–6 Third, the
expression of the plasma-membrane monocarboxylate
transporter (MCT) MCT1 (SLC16A1 [MIM 600682]) as well
as of other MCT isoforms7 is weak or undetectable in the
b cell.8 This conﬁguration has been proposed to reduce
loss-of-glucose carbon as pyruvate 6 and to avoid the un-
wanted stimulation of insulin release by lactate or
pyruvate.9
We recently identiﬁed exercise-induced hyperinsulin-
ism (EIHI) as a dominantly inherited hypoglycemic dis-
order characterized by inappropriate insulin secretion,
particularly during anaerobic exercise.10–12 Affected pa-
tients become hypoglycemic within 30 min after a short
period of anaerobic exercise. This pathology might result
from an inappropriate insulin release in response to ex-
ogenous catabolic metabolites such as lactate and pyru-
vate. Indeed, unlike unaffected individuals, patients re-
sponded to an acute exogenous pyruvate load with
prompt insulin release.11 This could be due to an over-
activity of MCTs in the b-cell plasma membrane, which
leads to the entry of pyruvate into the cell followed by its
metabolism with a consequent increase in ATP production
and insulin secretion. However, in earlier studies, no mu-
tations were detected in the coding regions of eight MCT
genes.11 Therefore, we decided to map the disease gene,
to identify the speciﬁc mutations, and to test their path-
ogenetic mechanisms in the b cell.
Material and Methods
Patients
Our study includes all 13 reported patients with EIHI. Twelve
patients belong to two Finnish pedigrees. Their clinical pheno-
types were described elsewhere.11 However, DNA for linkage anal-
ysis was available from only 10 of the 12 (ﬁg. 1). The fold response
of insulin secretion to an intravenous bolus of sodium pyruvate
provided the basis for differentiating affected and unaffected in-
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Figure 1. EIHI-affected families for genomewide linkage analysis and LOD scores on the chromosome 1 linkage region. A, EIHI-affected
families. Ten affected individuals (1, 2, 6, 9, 11, 13, 20, 26, 28, and 30) and nine unaffected (3, 8, 16, 17, 18, 19, 22, 23, and 27)
were genotyped and used for linkage analysis. The fold response of insulin secretion in response to pyruvate challenge is indicated in
italics above the symbol representing subjects tested, as a deﬁnitive phenotypic feature differentiating affected and unaffected indi-
viduals. B, Parametric LOD-score curve from genomewide linkage analysis of 435 microsatellite markers with use of a dominant model
of inheritance. The only genomewide-signiﬁcant peak is near the centromere of chromosome 1p (arrow). C, Higher resolution LOD-score
curve at the linkage peak on chromosome 1p. The dashed line represents the initial linkage analysis, and the solid line shows ﬁne-
mapping with ﬁve additional markers (marked with asterisks [*]).
dividuals. In all the unaffected individuals, this fold response has
a value of 1; in the affected individuals, it has a range of 2–10
(ﬁg. 1A).11 One patient is from Germany; the pathophysiology of
his insulin secretion during physical exercise has been studied in
detail.12
Genetic Linkage Analysis
Genomic DNA was extracted from whole blood (PureGene
[Gentra Systems]). A genomewide scan was performed with 430
microsatellite markers from the Linkage Mapping Set MD-10 (Ap-
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plied Biosystems) on a MegaBace 1000 capillary sequencer (Mo-
lecular Dynamics). The alleles were visualized using Genetic Pro-
ﬁler 1.1 or 2.0 software (Molecular Dynamics). For ﬁne mapping,
ﬁve microsatellites were added to the highest peak region. Ge-
notyping was performed at the Finnish Genome Center (genome
scan) and Clinical Research Center, Karolinska Institutet (ﬁne
mapping). Parametric linkage analysis with use of GENEHUNTER
(v. 2.1)13 was based on an autosomal dominant model with a
penetrance of 0.999 for heterozygotes, disease-allele frequency of
0.001, and phenocopy rate of 0.001. The positions of marker loci
were based on published maps (National Center for Biotechnol-
ogy Information [NCBI]).
Sequencing the Candidate Genes
One patient sample from both families and a control sample were
sequenced in both directions for the 5′ and 3′ UTRs and 2-kb
promoter region of the MCT1 gene (SLC16A1) and all exons and
1 kb of the promoter of the HMGCS2 gene. The primer sequences
are available on request. Puriﬁed (PCR puriﬁcation kit and gel-
extraction kit [Qiagen]) PCR products were sequenced using ABI
377 or ABI 3100 (Applied Biosystems). The Staden package14 was
employed for sequence alignment and comparison. Sequences
were checked against the published genome (NCBI). To verify the
frequency of the sequence changes in healthy individuals, 94
control samples from Finland and 32 control samples from Ger-
many were sequenced.
Quantitative RT-PCR Analysis of MCT1 mRNA Expression
Tissues were from male C57BL/6 mice (aged 8–10 wks). Islets of
Langerhans and pancreatic acini were collagenase isolated (for 3
min at 37C) and were hand picked under a dissection micro-
scope.15 Embryonic stem (ES) cells were obtained from L. Schoon-
jans (Thrombix, Center of Vascular Biology, Katholieke Univer-
siteit). MIN6 cells were obtained from E. Yamato (Division of Stem
Cell Regulation Research, Osaka UniversityMedical School). Total
RNA from tissues was isolated using TRIzol (Invitrogen) followed
by cleanup with RNeasy (Qiagen). Total RNA from islets, acini,
ES cells, and MIN6 cells was extracted using the Absolutely RNA
microprep kit (Stratagene). RNA quality and quantity were as-
sessed using the 2100 BioAnalyzer (Agilent Technologies) and the
NanoDrop ND-1000 spectrophotometer. One microgram of total
RNA was used for cDNA synthesis with the RevertAid H Minus
M-MuLV Reverse Transcriptase kit (Fermentas). QuantitativePCRs
(qPCRs) were performed using ABsolute QPCR mix (ABgene) on
a Rotor-Gene 3000 (Corbett Research). Quantiﬁcation of MCT1
mRNA-expression levels was normalized using polymerase II al-
pha (Polr2a) mRNA as internal reference. In each run, a MIN6
cell sample was used as a calibrator, and relative MCT1 mRNA
expression for this sample was set at 1.0. Reaction conditions and
sequences for primers and dual-labeled ﬂuorescent probes, syn-
thesized by Sigma Genosys, are available on request. Signiﬁcance
of differences in mRNA expression was assessed using the two-
tailed unpaired Student’s t-test. Standard curves were constructed
by amplifying serial dilutions of untreated mhAT3F cDNA (50 ng
to 0.64 pg) and by plotting cycle threshold (CT) values as a func-
tion of starting reverse-transcribed RNA, the slope of which was
used to calculate relative expression of the target gene.16
MCT1 Promoter Cloning and Site-Directed Mutagenesis
Bases from 1342 to 216A in the MCT1 promoter17 were am-
pliﬁed using primers 5′-ACT GTC TTC TAA TAT ACT GAA CTG
TTA TTG G-3′ and 5′-TCG TTT GCT TGT TCC AGT ACC CAC
GCA-3′. PCR was performed using genomic DNA as template. The
single 1.5-kb band was gel extracted and cloned into the pGEM
T-Easy vector (Promega). The promoter fragmentwas then excised
by digestion with EcoRI and was subcloned into the CFP-N vector.
HindIII and KpnI digestion of the resulting construct produced a
1,558-bpMCT1 promoter fragment, which was ligated into pGL3-
Basic vector (Promega).
A point mutation was introduced at position163 of theMCT1
promoter, with use of the QuickChange kit (Stratagene). A 1,595-
bp MCT1 promoter region containing the 25-nt duplication was
cloned using patient ﬁbroblast–derived genomic DNA, with use
of primers 5′-GGATGCCACACTGTCTTCTAATA-3′ and 5′- CCTC-
GTTTGCTTGTTCCAGTA-3′. The presence of the desired muta-
tions was conﬁrmed by sequencing.
MCT1 Promoter Assay
MIN6 b cells were seeded in a 24-well plate at a density of 2#
ml1 and were cotransfected for 4 h with 800 ng pGL3-pro-510
moter vector containing either wild-type or mutant hSLC16A1
promoter sequences, as detailed above, with 100 ng pRL-SV40
(Promega) containing Rotylenchulus reniformis luciferase gene as
a control for transfection efﬁciency, with 10 mg ml1 Lipofect-
AMINE in Opti-MEM Imedium (Invitrogen). Cells were harvested
48 h after transfection and were assayed for luciferase activity
with the Dual-Glow Luciferase Assay System (Promega). Promoter
activities were expressed as relative light units normalized against
control reporter (R. reniformis luciferase) activity in each extract,
as described elsewhere.18
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed according to standard protocols.19 In brief,
10-mg aliquots of MIN-6 nuclear extracts were preincubated with
0.5 mg of poly (dI-dC) and 1 ml of 100 mM dithiothreitol (DTT)
in a 30-ml reaction with a 4# buffer—containing 80 mM HEPES
(pH 7.6), 2 mM EDTA, 200 mM NaCl, 20% glycerol, 1.2 mg BSA,
and 40 mM DTT—for 15 min at room temperature. 32P-end–la-
beled double-stranded wild-type or mutant probes were added,
and the mixture was incubated for 15 min at room temperature.
In competition assays, cold probes were incubated with 100- and
200-molar excess for 15 min at room temperature before the ad-
dition of the labeled probes. The samples were electrophoresed
on 4.5% nondenaturing polyacrylamide gels in 1# TBE at 240 V
in a cold room. The radioactive pattern was visualized by auto-
radiography and was quantiﬁed by PhosphorImager scanning
(Fuji Photo). Oligonucleotides were normal probes (5′-GCC CGG
CCA GAC AAA GTG GTG AGC TGC GAC-3′ and 5′-GTC GCA
GCT CAC CAC TTT GTC TGG CCG GGC-3′) and mutant probes
(5′-GCC CGG CCA GAC AAA ATG GTG AGC TGC GAC-3′ and
5′-GTC GCA GCT CAC CAT TTT GTC TGG CCG GGC-3′).
Experiments with Patient Fibroblasts
Primary ﬁbroblast cell lines were generated from skin-biopsy sam-
ples of one patient from each family and from four healthy age-
matched control individuals. Steady-state levels of MCT1 and
MCT4 protein and mRNA were measured by western blotting18
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and quantitative RT-PCR, respectively. Total RNA was isolated
from cultured ﬁbroblasts (TRI Reagent [Sigma]) and was DNAse
treated (DNA-free [Ambion]) as recommended by the supplier.
First-strand cDNA was synthesized from 2 mg total RNA. TaqMan
primers and probes for quantitative RT-PCR were kindly donated
by AstraZeneca (R&D Charnwood). The dual-labeled ﬂuorogenic
probes consisted of oligonucleotides with the 5′ reporter dye 6-
carboxyﬂuorescein (FAM) and the 3′ Black Hole Quencher 1 dye
(BHQ1). Primer and probe sequences are available on request.
Lactate transport into the ﬁbroblasts was determined by mea-
surement of the decrease in intracellular pH with use of the ﬂuo-
rescent pH-sensitive dye 2′–7′-bis (carboxyethyl)-5–6-carboxy-
ﬂuorescein (BCECF) as described elsewhere.20
Results
Identiﬁcation of SLC16A1 Mutations
We diagnosed EIHI for 13 patients, 12 from two families
and one unrelated patient. A total of 430 microsatellite
markers were genotyped in 10 affected and 9 unaffected
individuals (ﬁg. 1A). Linkage analysis with a dominant
model revealed the strongest evidence of linkage on chro-
mosome 1, with total maximum LOD score 2.53 (ﬁg. 1B).
Five markers were added to the linkage peak, with an in-
crease of maximum LOD score to 3.6 (ﬁg. 1C). Four ad-
jacent markers showed signiﬁcant linkage by single-point
analysis. A haplotype formed bymarkersD1S250, D1S534,
D1S498, and D1S1595 was present in all affected but no
unaffected individuals of the larger family. Nor was it pre-
sent in the other pedigree, suggesting that the families
have independent mutations.
Several candidate genes with potential relevance were
present within the linkage peak. We initially elected three
of them for sequencing. The PHGDH gene, which encodes
phosphoglycerate dehydrogenase (MIM 606879), was lo-
cated 580 kb from peak marker D1S534. The HMGCS2
gene, which encodes mitochondrial 3-hydroxy-3-meth-
ylglutaryl-coenzyme A synthase 2 (MIM 600234) was 620
kb from D1S534, and the SLC16A1 gene, which encodes
theMCT1 protein (MIM 600682), was located 6.2Mb from
the peak marker. We sequenced all three genes; no se-
quence variants were found in any exons of HMGCS2, but
two variants in PHGDH—rs562038 and rs543703 in exon
1 and exon 11, respectively—were found in the EIHI-af-
fected families. Sequencing of SLC16A1 was focused on
the 5′ UTR and promoter regions (2 kb upstream of the
transcription start site) because no mutations had been
found previously in the coding region.11 A previously un-
known SNP (a GrA change) in exon 1 at position 163
relative to the transcription start site, was found in the
affected individuals of pedigree 1 (ﬁg. 2A). In a patient
from pedigree 2, a 25-bp duplication was found between
nucleotide positions 23 and 24. The duplicated se-
quence also contained an ArT change (ﬁg. 2A and 2C).
Sequencing of these putative mutations in at least 94 sam-
ples from Finland and Germany revealed not a single oc-
currence in healthy controls, excluding with 184% prob-
ability that they were polymorphisms with a frequency of
1%. In the German patient,10,12 several sequence variants
were found, including a 2-bp insertion (ﬁg. 2B).
Database searching (TESS: Transcription Element Search
System) revealed that the three putative mutations lie
within the binding sites of several transcription factors
(ﬁg. 2A and 2B). A binding site for nuclear matrix protein
1 (YY1) was predicted at the point-mutation site in the
mutant sequence of pedigree 1. The same point mutation
disrupted the binding sites of two potential transcriptional
repressors: albumin negative factor (ANF) and AML-1a
(ﬁg. 2A). The duplication variant introduced additional
binding sites for the ubiquitous transcription factors sim-
ian-virus-40-protein-1 (Sp1), upstream stimulatory factor
(USF), andmyeloid zinc ﬁnger 1 (MZF1) (ﬁg. 2A). The third
mutation resulted in loss of a GATA-1–binding site (ﬁg.
2B). These predictions were consistent with the hypothe-
sis that the identiﬁed mutations affect regulation of the
SLC16A1 gene.
Functional Consequences of the Mutations
To establish potential functional consequences of the
163 GrA variant in pedigree 1, we performed EMSA.
Distinct differences were seen in the protein-binding
activity of this site in nuclear extracts, with binding to
the common variant increasing progressively in MIN6,
SyH-SY5Y, and HeLa cells (ﬁg. 3). Moreover, in each cell
type, a higher degree of binding to the mutated site
was apparent, except for one low–molecular weight band
that was lost in the mutated sequence in MIN6 cells (ﬁg.
3). Competition assays conﬁrmed the speciﬁcity of the
probes. The EMSA result provided further evidence of al-
tered transcriptional regulation introduced by the GrA
mutation.
Since it was not feasible to study SLC16A1 promoter
activity in patient b cells, mRNA expression in skin ﬁbro-
blasts from two EIHI-affected patients and four control
individuals was assayed for two genes, SLC16A1 (which
encode MCT1) and SLC16A3 (which encodes MCT4). As
measured by quantitative RT-PCR (normalized against 18S
RNA), MCT1 mRNA was two to three times higher in both
patients than it was in any control, whereas MCT4 mRNA
levels were similar in patients and controls. To determine
whether the increase in SLC16A1 mRNA in patient ﬁbro-
blasts led to increased expression of MCT1 and monocar-
boxylate transport activity, western blotting and transport
assays were performed (ﬁg. 4). There was no evidence that
the patient ﬁbroblasts showed greater expression or activ-
ity than did the control ﬁbroblasts. This lack of correlation
between levels of MCT1 mRNA and MCT1 protein is well
established in a variety of tissues and is thought to result
from posttranscriptional regulation involving the unusu-
ally long (1.6 kb) 3′ UTR of MCT1 mRNA.21,22 In most
tissues, such as ﬁbroblasts, the expression ofMCT1protein
may be relatively insensitive to the level of MCT1 mRNA,
which is controlled to a much greater extent by transla-
tional mechanisms. However, in the b cell, where the basal
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Figure 2. Alignment of nucleotide sequence of the 5′ region of the normal and mutated MCT1 gene. The noncoding exon 1 is shown
in bold black font, and the transcription start site is indicated in blue. Numbers in boxes indicate nucleotide positions. A, Mutations
found in Finnish families. A SNP in exon 1 at position 163, found in pedigree 1, is shown in green, and the duplicated sequence of
pedigree 2 is shown in red. B, Mutation found in a German patient. Speciﬁc binding sites of transcription factors are indicated with
arrows, red for gain in mutant and blue for loss in mutant. C, Sequences at the duplication site from a heterozygous patient of pedigree
2. The arrow bar indicates the duplicated sequence in one of two homologous chromosomes.
expression of MCT1 mRNA is extremely low, MCT1 pro-
tein expression may respond signiﬁcantly to the increased
mRNA production that results from the activated pro-
moter in the patients.
The potential functional relevance of the above ﬁndings
for b cells was tested by measuring MCT1 mRNA levels in
a number of mouse tissues, including puriﬁed pancreatic
acini and islets, clonal murine b cells (MIN6), and a cells
(aTC1-9) (ﬁg. 5A and 5B). Compared with all other tissues,
MCT1 mRNA was very low or absent in b cells and islets,
consistent with differences reported elsewhere in lactate-
transport activity4 and MCT1 levels8 in pancreatic b cells.
Transfection of MIN6 cells with an MCT1 promoter-lucif-
erase reporter construct including the nucleotides from
1342 to 216 revealed a 3.5-fold ( ) increase inP ! .001
promoter activity after the GrA mutation at position 163
(ﬁg. 5C, mutation P1). A similar (two-to-threefold) in-
crease in the MCT1 promoter activity induced by this mu-
tation was seen when the same promoter-luciferase re-
porter constructs were expressed in L6 myoblasts and
HeLa and CHO cells (data not shown). Transfection of the
MIN-6 cells with a promoter construct, including the 25-
nt duplication found in pedigree 2, resulted in an even
more dramatic (10-fold, ) stimulatory effect onP ! .001
transcription (ﬁg. 5C, mutation P2).
Discussion
We identify here linkage to mutations in the SLC16A1
gene in two pedigrees of patients with EIHI. Whereas the
linkage interval was relatively large, we failed to detect
mutations in other likely potential genes in this region,
but we demonstrated instead that two of the three
SLC16A1 gene mutations lead to profound increases in
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Figure 3. EMSAs performed using 30-bp fragments encompassing
the polymorphism 163 GrA found in exon 1 of the SLC16A1
gene. Protein extracts from three different cell lines were used:
lanes 1–4, MIN-6 cells; lanes 5–6, SH-SY5Y cells; and lanes 7–8,
HeLa cells. N denotes normal probe “G,” and M denotes mutant
probe “A.” Lanes with asterisks (*) denote competition assays with
unlabeled variants of the probe. Arrows indicate the differential
afﬁnity in the binding (upper arrow) and disruption of a putative
binding site (lower arrow).
Figure 4. A, MCT1 and MCT4 mRNA expression in control and
patient ﬁbroblasts. Expression was normalized against ribosomal
18S expression. Data are the mean (SEM) of four independent
experiments, each involving triplicate measurements. B, Transport
assay with use of pH-sensitive BCECF dye. Data are the mean
(SEM) of 8–14 individual cells per assay. C, Western-blot data
showing MCT1 and MCT4 expression in cultured ﬁbroblast cells.
Whole-cell protein extracts were prepared from the same batch of
cells that were assayed for lactate transport and were resolved
using SDS-PAGE. Western blotting was performed with antibodies
to MCT1 and MCT4, as indicated.
the transcription of this gene. These changes are likely to
lead to increased levels of MCT1 protein, and hence trans-
port activity, selectively in b cells where, in healthy sub-
jects, MCT1 levels are extremely low. The present study
thus suggests that human b cells, like those of rodents,4,8
may be uniquely conﬁgured in this way. Low levels of
plasma-membrane–lactate transport activity ensure that
the uptake of lactate and pyruvate—and hence the in-
appropriate, and potentially fatal, secretion of insulin—
does not occur during exercise. In patients with EIHI, se-
lective increases in b-cell MCT1 expression may permit
pyruvate or lactate to stimulate b-cell mitochondrial me-
tabolism, leading to increased intracellular ATP/adenosine
diphosphate ratios, the closure of KATP channels,
23 inhi-
bition of adenosine monophosphate–activated protein ki-
nase,24 plasma membrane depolarization, Ca2 inﬂux, and
insulin exocytosis.1 Given the very low lactate dehydro-
genase (LDH) activity in b cells,6 the very efﬁcient pyru-
vate oxidation by b-cell mitochondria,23 and the fact that
overexpression of both MCT1 and LDH was required for
a secretory response to lactate in isolated islets,9 we suspect
that changes in circulating pyruvate, rather than lactate,
are the principal trigger for insulin secretion in patients
with EIHI.11
Our data are consistent with silencing of the MCT1
promoter in b cells by inhibitory transcription factors
that remain to be characterized. Likewise, duplication of
a cis-acting region, as seen in one pedigree, may provide
increased basal transcriptional activity. In any case, the
resulting increase in transcription, from near zero to a
signiﬁcant level, seems likely to lead to an increase
in MCT1 activity in the b cell. Since our normal MCT1-
promoter construct shows signiﬁcant but low activity
in MIN6 cells, additional posttranscriptional inhibitory
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Figure 5. A, Ex vivo MCT1 mRNA expression in a panel of mouse tissues, including hand-picked pancreatic islets of Langerhans and
pancreatic acini, as well as mouse ES cells and the insulin secreting cell line MIN6. MCT1 mRNA was quantiﬁed via quantitative RT-PCR
and was normalized for RNA Polymerase II alpha (Polr2a). All PCR samples, including two MIN6 cell replicates, were calibrated against
extract from a MIN6 cell that was scaled at a ratio of 1.0. Data are means (SEM) of three independent biological replicates. The
mouse tissues are ranked with increasing expression level. Inset, Pancreatic islets versus acini with an enlarged scale; signiﬁcance of
difference in the expression ratio was calculated with the unpaired two-tailed Students’ t-test. B, Tissue-speciﬁc MCT1 mRNA expression.
Real-time RT-PCR was performed on cDNA isolated from clonal pancreatic b cells (MIN6), a-cells (a-TC), hepatoma (mhAT3-F) as described
in the “Material and Methods” section. Expression was normalized against cyclophilin, and results were expressed as fold change (SEM)
over MCT1 expression in MIN6. C, MCT1 promoter activity in MIN6 b cells. Activity was measured as the ratio of ﬁreﬂy:renilla luciferase
activity after transfection with the control plasmid (pGL3), the wild-type promoter (wtMCT1), or the mutations found in the two pedigrees
(P1 and P2). Data are presented as mean (SEM) for six replicates in each case in three separate experiments.
mechanisms are likely to exist to further inhibit expres-
sion of MCT1 protein.
In conclusion, we describe here a novel mechanism for
human disease. The failed silencing of the expression of
a cell-membrane transporter (MCT1) in a speciﬁc cell type
(pancreatic b cells) leads to an inappropriate physiological
response in patients with EIHI, characterized by inappro-
priate insulin release during anaerobic exercise.
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